GlassScriptPhysician profile
Amy Hussey
NPI 1861755506
$4,433.11
in general payments reported to CMS, 2019-2025
30 companies · $1,026 in 2025
The $1,026 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.92 · 2021: $21.14 · 2022: $285 · 2023: $1,441 · 2024: $1,649 · 2025: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,116.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $758.00 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $567.56 | 2023-2025 | |
| Lilly USA, LLC | $497.53 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $402.16 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $322.90 | 2022-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.06 | 2023-2025 | Jardiance |
| Dexcom, INC. | $217.92 | 2022-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $213.27 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $191.88 | 2023-2025 | Xarelto, Spravato |
| Idorsia Pharmaceuticals US INC | $185.01 | 2023 | Quviviq |
| Pfizer INC. | $171.40 | 2022-2025 | |
| Inspire Medical Systems, INC. | $71.55 | 2024-2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $69.19 | 2025 | |
| Esperion Therapeutics, INC. | $61.83 | 2024-2025 | Nexletol |
| Amgen INC. | $59.84 | 2024-2025 | Otezla, Repatha, Repatha |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.53 | 2022-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $48.43 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $39.67 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $34.00 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $31.19 | 2023 | Eliquis |
| Antares Pharma, INC. | $22.28 | 2023 | Tlando, Nocdurna, Xyosted |
| Novartis Pharmaceuticals Corporation | $21.93 | 2022 | |
| Genentech USA, INC. | $21.14 | 2021 | |
| Halozyme INC | $19.50 | 2023 | |
| Phadia US INC. | $19.19 | 2022 | |
| Sanofi Pasteur INC. | $18.90 | 2023 | |
| Lundbeck LLC | $17.27 | 2024 | Vyepti |
| Otsuka America Pharmaceutical, INC. | $15.26 | 2025 | Rexulti |
| Organon LLC | $13.16 | 2022 | |
| Phathom Pharmaceuticals, INC. | $5.56 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Hussey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.